Gosset Ownership
Private
Employees
~125
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Sail Biomedicines General Information
Sail Biomedicines is developing a next-generation platform for fully programmable RNA medicines. Its lead technology—Endless RNA—enables durable protein expression in vivo. The company’s preclinical pipeline includes programs targeting infectious disease, rare disease, metabolism, and autoimmune indications. No clinical results have been reported as all programs remain at the preclinical stage as of early 2025.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Flagship Pioneering is a key backer/incubator., Received grants for malaria work but no specific partners named.
Sail Biomedicines Funding
No funding data available
To view Sail Biomedicines's complete valuation and funding history, request access »